PSoHO results: Real-world long-term analysis of biologics in patients with moderate-to-severe PsO

Results from the international, observational Psoriasis Study of Health Outcomes (PSoHO) investigation into the comparative effectiveness and durability of biologic treatments for patients with moderate-to-severe psoriasis (N = 1,981) over 24 months were published in Dermatology and Therapy by Pinter et al.

Key data: Patients who received anti-interleukin (IL)-17A biologics demonstrated higher Psoriasis Area and Severity Index (PASI)100 durability rates at 24 months compared with anti-IL-12/23, anti-IL-23, and anti-tumor necrosis factor (TNF)-α biologics (12.2%, 5.5%, 10.7%, and 4.2%, respectively). PASI90 durability rates for anti-IL-17A treatments were superior to anti-IL-12/23 and anti-TNF-α biologics, but similar to anti-IL-23 therapies (26.6%, 12.6%, 9.4%, and 24.8%, respectively). Among the biologics, ixekizumab (Ixe) showed improved PASI100 and PASI90 durability vs secukinumab (Sec), tildrakizumab (Tild), guselkumab (Gus), adalimumab (Ada), and ustekinumab (Ust), with unadjusted response rates for PASI100 durability of 12.6%, 10.4%, 4.2%, 10.2%, 3.5%, and 5.5%, respectively, and similar durability to risankizumab (Ris), which had a PASI100 durability response rate of 13.5%. 

Key learning: Results suggest that anti-IL-17A biologics, particularly Ixe, provide superior long-term effectiveness and durability in achieving and maintaining PASI100 responses in patients with moderate-to-severe psoriasis over 24 months compared with other classes of biologics, emphasizing the importance of selecting treatments that deliver and maintain skin clearance over extended treatment periods.